Related Experiment Video
Updated: Jul 17, 2025

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
Published on: June 5, 2019
A proposal for new definition (s) and management approach to paediatric refractory ITP: Reflections from the
Cindy Neunert1, Katja M J Heitink-Polle2, Michele P Lambert3,4
1Vagelos College of Physicians and Surgeons, Columbia University Medical School, New York, New York, USA.
Insights
Most childhood immune thrombocytopenia (ITP) resolves within a year. Refractory ITP (rITP) in children presents challenges, prompting a review of its features, classifications, and predictors.
Area of Science:
- Pediatric Hematology
- Immunology
- Clinical Research
Background:
- Immune thrombocytopenia (ITP) in children is typically self-limited, with most normalizing platelet counts within 12 months.
- First-line treatments like IVIG and corticosteroids are highly effective for ITP.
- Second-line therapies show good response rates, but some children develop refractory ITP (rITP).
Purpose of the Study:
- To review the clinical characteristics of refractory ITP in pediatric patients.
- To outline proposed classifications for rITP in children.
- To explore potential predictors for identifying children with rITP.
Main Methods:
- Literature review of clinical features of pediatric rITP.
- Analysis of proposed classification systems for rITP.
- Exploration of predictive factors for refractory disease course.
Main Results:
- Majority of pediatric ITP cases are mild and self-limiting.
- Effective first and second-line treatments exist, but a subset of children develop rITP.
- Understanding rITP features, classification, and predictors is crucial for management.
Conclusions:
- Refractory ITP in children requires specific attention due to poor treatment response.
- Further research into classification and predictors can guide management strategies for pediatric rITP.
- Identifying children at risk for rITP may improve therapeutic outcomes.
Abstract:
Immune thrombocytopenia (ITP) in children is a relatively mild and self-limited disorder with the majority of children demonstrating normalization of platelet count by 12 months from diagnosis. Because of this, many children with ITP can be observed without the need for treatment. When needed, treatment with either intravenous immunoglobulin (IVIG) or corticosteroids is highly effective (>80% IVIG and >95% corticosteroids). For those children who require second-line therapies, response rates of >60% are seen with both the thrombopoietin-receptor agonists and rituximab. Despite this, some children will have 'refractory' ITP (rITP) with poor or transient responses to platelet-raising therapies. Here, we review the clinical features of rITP in children, outline proposed classifications and explore potential predictors for children with rITP.
More Related Videos
12:40Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
11:06Combining Intravital Fluorescent Microscopy IVFM with Genetic Models to Study Engraftment Dynamics of Hematopoietic Cells to Bone Marrow Niches
Published on: March 21, 2017
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Pyelonephritis II: Diagnostic Studies and Management